Form 4: Vertex Pharmaceuticals EVP, COO Stuart A. Arbuckle Reports Acquisition of Restricted Stock Units

Stuart A. Arbuckle, EVP, COO of Vertex Pharmaceuticals, reports the acquisition of 7,903 restricted stock units.

Summary

• Stuart A. Arbuckle, the EVP, COO of Vertex Pharmaceuticals, filed a Form 4 on February 14, 2025.
• The report details a transaction on February 12, 2025, where Arbuckle acquired 7,903 shares of common stock in the form of restricted stock units.
• These restricted stock units were awarded at a price of $0 per unit.
• Following the transaction, Arbuckle directly owns 77,446 shares of Vertex Pharmaceuticals common stock.
• Additionally, he indirectly owns 140 shares through a 401(k) plan.
• The restricted stock units vest in installments starting on February 24, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and insider confidence.

Positives

• The acquisition of restricted stock units suggests confidence in the company's future performance from the executive.

Future Outlook

The restricted stock units vest in installments beginning on 02/24/2026, incentivizing the executive to contribute to the company's long-term success.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders.

Stakeholder Impact

• The acquisition of restricted stock units aligns the executive's interests with those of the shareholders.

Key Dates